Antares Pharma, Inc. (ATRS)
ATRS Price and Sentiment
ATRS Latest news
Antares Pharma Initiates Phase I Study For ATRS-1902 For Adrenal Crisis Rescue
2021-09-30 09:00Pharmacokinetic data results expected in 1Q 2022 Pharmacokinetic data results expected in 1Q 2022
Antares Pharma to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
2021-09-08 08:30EWING, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, will participate and host investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference being held on September 13-15, 2021.
Got $1,000? These 2 Bargain-Bin Biopharma Stocks Might Be Worth Buying
2021-08-27 10:15These healthcare stocks have their warts, but the price is right for long-term investors.
Antares Pharma's (ATRS) CEO Robert Apple on Q2 2021 Results - Earnings Call Transcript
2021-08-05 15:15Antares Pharma's (ATRS) CEO Robert Apple on Q2 2021 Results - Earnings Call Transcript
Antares Pharma Reports Second Quarter 2021 Financial and Operating Results
2021-08-05 07:00Increased Revenue 39% Year-Over-Year to $45.0 Million
Antares Pharma (ATRS) Earnings Expected to Grow: Should You Buy?
2021-07-29 16:46Antares Pharma (ATRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Antares Pharma to Report Second Quarter 2021 Financial and Operating Results
2021-07-28 08:30EWING, N.J., July 28, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced it will release its second quarter 2021 financial and operating results on Thursday, August 5, 2021, before the market opens.
Antares To Start Testing ATRS-1902 With Injector Technology In Patients With Adrenal Crisis
2021-07-22 09:59The FDA has accepted Antares Pharma Inc's (NASDAQ: ATRS) Investigational New Drug Application (IND) for ATRS-1902 for adrenal crisis rescue. The active IND enables Antares to initiate a Phase 1 study for ATRS-1902 for acute adrenal insufficiency, known as an adrenal crisis, in adults and adolescents.
Antares Pharma Announces FDA Acceptance of IND Application for ATRS-1902 for Adrenal Crisis Rescue
2021-07-22 08:30EWING, N.J., July 22, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug Application (IND) for ATRS-1902 for adrenal crisis rescue. The active IND enables Antares to initiate a Phase 1 clinical study for ATRS-1902 for the treatment of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using a novel proprietary auto-injector platform to deliver hydrocortisone.
7 Penny Stocks For Your Watch List This Week If You Like Biotech In July
2021-07-05 12:29Looking for biotech penny stocks to watch right now? Here are 7 for your list this week.